June 21, 2019 article JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut DOI: 10.1136/gutjnl-2019-318448 OpenAlex Authors 0 Author list not loaded yet. Cited by 3 stored of 148 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants 2023 Clinical Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access 1 citations Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial 2022 Intestinal Research article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access 15 citations Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement 2020 Annals of the Rheumatic Diseases article Medicine Rheumatoid Arthritis Research and Therapies Open access 300 citations 3 results References 0